Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot could help raise platelet levels in chronic blood disorder

NCT ID NCT05070845

Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called PF-06835375 in adults with moderate to severe primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. The goal is to see if the drug can safely increase platelet counts. About 91 participants with persistent or chronic ITP will receive multiple injections and be monitored for response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 91 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2022

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of Primary ITP. Ongoing ITP (platelet counts \<50 x 109/L) \[No severe bleeding within 1 month or during screening\] AND Persistent ITP (3 to 12 months) or Chronic ITP \>12 months Exclusion Criteria: * Bleeding event according to the WHO grading scale ≥2 occurring ≤4 weeks prior to screen OR a current bleeding event that, in the opinion of the investigator, requires treatment with standard of care therapy OR require blood or blood products during screening * Splenectomy within 3 months of randomization or planned during the study duration.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Primary immune thrombocytopenia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autoimmune thrombocytopenic purpura primary thrombocytopenia Purpura, Thrombocytopenic, Idiopathic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Primary immune thrombocytopenia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    27 sites in 7 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AIDPORT Sp. z o.o.

    RECRUITING

    Skórzewo, Greater Poland Voivodeship, 60-185, Poland

  • Addenbrooke's Hospital

    RECRUITING

    Cambridge, Cambridgeshire, CB2 2QQ, United Kingdom

  • Calvary Mater Newcastle

    RECRUITING

    Waratah, New South Wales, 2298, Australia

  • Derriford Hospital

    RECRUITING

    Plymouth, Devon, Pl6 8DH, United Kingdom

  • East Carolina University

    RECRUITING

    Greenville, North Carolina, 27834, United States

  • Fakultni nemocnice Hradec Kralove

    RECRUITING

    Hradec Králové, 500 05, Czechia

  • Fakultni nemocnice Kralovske Vinohrady

    RECRUITING

    Prague, 100 34, Czechia

  • Fakultni nemocnice Ostrava

    RECRUITING

    Ostrava - Poruba, 708 52, Czechia

  • Flinders Medical Centre

    RECRUITING

    Bedford Park, South Australia, 5042, Australia

  • Hammersmith Hospital

    RECRUITING

    London, W12 0HS, United Kingdom

  • ICON Cancer Centre - Kurralta Park

    RECRUITING

    Kurralta Park, South Australia, 5037, Australia

  • InterHem

    ACTIVE_NOT_RECRUITING

    Bialystok, 15-732, Poland

  • Klinika Hematologii i Transplantologii Uniwersyteckie Centrum Kliniczne

    ACTIVE_NOT_RECRUITING

    Gdansk, 80-214, Poland

  • Komárom-Esztergom Vármegyei Szent Borbála Kórház

    NOT_YET_RECRUITING

    Tatabánya, H-2800, Hungary

  • Liverpool Hospital

    RECRUITING

    Liverpool, New South Wales, 2170, Australia

  • McGill University Health Centre

    RECRUITING

    Montreal, Quebec, H4A 3J1, Canada

  • Petz Aladár Egyetemi Oktató Kórház

    RECRUITING

    Győr, 9024, Hungary

  • Pratia Onkologia Katowice

    RECRUITING

    Katowice, 40-519, Poland

  • Pécsi Tudományegyetem Klinikai Központ

    ACTIVE_NOT_RECRUITING

    Pécs, Baranya, 7624, Hungary

  • Royal Perth Hospital

    RECRUITING

    Perth, Western Australia, 6000, Australia

  • Semmelweis University

    RECRUITING

    Budapest, 1088, Hungary

  • Slade Pharmacy

    RECRUITING

    Mount Kuring-Gai, New South Wales, 2080, Australia

  • Somogy Megyei Kaposi Mór Oktató Kórház

    RECRUITING

    Kaposvár, Somogy County, 7400, Hungary

  • South West Radiology

    RECRUITING

    Liverpool, New South Wales, 2170, Australia

  • The Alfred Hospital

    RECRUITING

    Melbourne, Victoria, 3004, Australia

  • The Royal Cornwall Hospital

    RECRUITING

    Truro, England, TR1 3LJ, United Kingdom

  • Tolna Varmegyei Balassa Janos Korhaz

    NOT_YET_RECRUITING

    Szekszárd, 7100, Hungary

  • Unity Health Toronto, St. Michael's Hospital

    RECRUITING

    Toronto, Ontario, M5B 1W8, Canada

  • Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu

    RECRUITING

    Wroclaw, 50-367, Poland

  • Uniwersytecki Szpital Kliniczny w Poznaniu

    ACTIVE_NOT_RECRUITING

    Poznan, 60-569, Poland

  • Vseobecna fakultni nemocnice v Praze

    RECRUITING

    Prague, 12808, Czechia

More trials for these conditions

Other studies related to the condition(s) this trial covers.